The α 4/6 βδ-containing GABA A receptors are involved in a number of brain diseases. Despite the potential of a δ-selective imaging agent, no PET radioligand is currently available for in vivo imaging. Here, we report the characterization of DS2OMe (1) as a candidate radiotracer, 11
■ INTRODUCTION
γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system and exerts its major physiological effect via interaction with ionotropic GABA A receptors (GABA A Rs). The GABA A Rs are assembled from a variety of subunits (α 1−6 , β 1−3 , γ 1−3 , δ, ε, θ, π, and ρ 1−3 ) forming hetero-or homopentameric complexes in various combinations. 1, 2 The subunit composition of GABA A Rs appears to differ with subcellular localization, which dictates the type of inhibition mediated. 3 The majority of GABA A Rs has the general stoichiometry of 2α, 2β, and 1γ subunits. 4 However, in a subpopulation of receptors, the δ-subunit replaces the γ-subunit. δ-subunit-containing GABA A Rs, for example, α 4 βδ, α 6 βδ, and α 1 β 2 δ, are primarily found in peri-or extrasynaptic locations where they mediate tonic inhibition, distinct from the fast and transient synaptic inhibition. 5, 6 Aberrant tonic inhibition mediated by α 4/6 βδ-containing receptors has been implicated under various pathophysiological conditions and related to discrete brain regions, 1 including stroke (cortex), 7 Angelman syndrome (cerebellum), 8 sleep-related disorders (thalamus), 9 and depression (hippocampus). 10 Therefore, these receptors have received a great deal of attention in the last decades as potential drug targets. 11 Consequently, development of selective tool compounds and diagnostics to further understand the pharmacology and physiological roles of these receptors will prove therapeutically important.
Among the orthosteric ligands reported, the functional δ-preferring orthosteric agonist THIP (gaboxadol) (Figure 1 ) has been pursued as a novel treatment for insomnia, reaching phase III clinical development. Gaboxadol is at present in phase III clinical trials for treatment of Angelman syndrome. 12 The imidazopyridine DS2, a functionally selective α 4 / 6 β 3 δ positive allosteric modulator (PAM), relative to its action at α 4 β 3 γ 2 and α 1 β 3 γ 2 receptors, has been reported. 13, 14 However, poor brain penetration precludes the use of DS2 for in vivo studies. 15 Recently, we reported a structure−activity study on the δ-selective imidazopyridine DS2 (Figure 1) 17−20 Since the δ-containing GABA A Rs are potentially involved in the pathogenesis and symptoms of several disorders in the central nervous system, a positron emission tomography (PET) tracer would be a valuable tool. Inspired by the structure−activity study mentioned above, we herein report the identification, radiosynthesis, and in vivo PET studies of a low micromolar potency, selective, and brain-penetrant PAM of δ-containing GABA A Rs ([ 11 C]DS2OMe, [ 11 C]1), in pig, as a promising lead candidate for imaging the δ-containing GABA A Rs.
■ RESULTS AND DISCUSSION
Initially, a potential 11 C-labelling site in the core scaffold of DS2 was identified based on the reported structure−activity study and the experience obtained on the chemistry involved. 16 Since the p-hydroxy analogue 2 (see Scheme 1) appears as an attractive precursor amenable for radiolabeling via conventional 11 C-methylation, the [ 11 C]-p-methoxy analogue of DS2 ([ 11 C]1) was selected as the candidate radiotracer.
To probe the applicability of [ 11 C]1 as a specific radiotracer for the δ-containing GABA A Rs, the selectivity profiles of 1 and DS2 as PAMs were compared using a fluorescence-based FLIPR membrane potential (FMP) assay, based on the transient expression of human α 1/4/6 and β 2 subunits in a HEK293 Flp-In cell line, stably expressing the human δ-subunit, 21 or γ 2 instead of δ for comparison. To this end, the concentration of GABA corresponding to GABA EC 20 was first determined from the full concentration−response curves of GABA for each of the tested receptors (Table 1) . Then, 1 and DS2 were tested as PAMs in the presence of the determined EC 20 GABA concentration. To investigate the importance of the α-subunit for PAM activity, the subtypes, α 1 β 2 δ, α 4 β 2 δ, and α 6 β 2 δ, were compared. Full concentration−response curves showed that 1 and DS2 displayed near equipotent PAM activities (1−4 μM) at the different α-subunit-containing receptors (Table 1, Figure 2 ). In parallel, to confirm δ-subunit selectivity, 1 was also tested as a PAM at α 6 β 2 γ 2s . As shown, neither DS2 nor 1 had any effect at this non-δ-containing receptor subtype when tested at concentrations up to 10 μM (Table 1, Figure 2 ). These data summarizes 1 as a novel δ-selective DS2-analogue with low micromolar PAM activity. The cell line stably expressing the δ-subunit has previously been used to study DS2 at α 4 β 1 δ versus binary α 4 β 1/3 receptors using both the FMP assay and whole-cell patch-clamp recordings, confirming that DS2 is δ-selective.
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The selectivity was further explored in The National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH-PDSP) (Supporting Information Table S1 ), where binding affinity and cross selectivity of 1 to a large panel of brain targets was assessed. 1 did not show significant affinity (K i > 10 μM) for other tested biogenic receptors and transporters (45 in total).
The high selectivity for δ-containing GABA A Rs establish 1 as an interesting compound, as a PET radiotracer candidate, for further studying the δ-containing GABA A Rs. Furthermore, since O-demethylation in general is a major metabolic pathway, the O-demethylated compound may be the major metabolite for 1. Therefore, radiolabeling of the methoxy group, resulting in [ 11 C]1 via radiomethylation of the hydroxyl analogue (2), was rendered the most suitable strategy to avoid/limit radioactive metabolite formation.
Consequently, radiosynthesis of 1 was probed to obtain the corresponding [ 11 C]1. To obtain the hydroxylated precursor, 2, a three-step procedure was applied, as previously reported, 16 using 2-aminopyridine, thiophen-2-carbaldehyde, and potassium cyanide in a multicomponent reaction, followed by amide-bond formation using 4-acetoxybenzoyl chloride. The removal of the acetoxy group was accomplished with 5 M NaOH in tetrahydrofuran at room temperature.
The nonradiolabeling experiment was performed by using methyl triflate and 2 M NaOH in acetone for 3 min at 80°C to enable the introduction of O-methyl into 2 affording the target compound 1.
The radiosynthesis of [ 11 C]DS2OMe ([ 11 C]1) was performed in a fully automated system. [
11 C]CH 3 OTf was dissolved in acetone containing the precursor and base and reacted for 5 min at 60°C. Isolation of the final radiotracer, see Scheme 1, could be achieved via semipreparative highperformanec liquid chromatography (HPLC) with a total synthesis time of 37 min (Supporting Information Figures S1  and S2 ).
The radiolabeled compound [ 11 C]1 was produced with a good radiochemical yield of 19.9 ± 1.2% (n = 3, decay corrected), sufficient chemical and radiochemical purity of >95%, and very high molar activities of 188−215 GBq/μmol.
Using the radiochemistry described and delineated in Scheme 1, [
11 C]1 was prepared for evaluation in in vivo PET imaging studies in a domestic pig using a high-resolution research tomography (HRRT) PET scanner. As an exper- 
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Article imental animal, the pig allows us to acquire the arterial input function necessary for kinetic modelling of the data. The pig also has a larger and gyrenchephalic brain giving it a higher translational value compared to, for example, rats. [
11 C]1 successfully entered the pig brain, with the radioligand uptake being fairly uniform across different brain regions ( Figure 3A) . From the time−activity curves, it is also evident that [
11 C]1 has fast tracer kinetics in the four different regions measured, meaning that the retention of the tracer in the brain is limited ( Figure 3B ). Two other baseline PET experiments were conducted in two other pigs, showing a similar uniform uptake and fast tracer kinetics (data not shown).
In one pig, we performed first the baseline scan and subsequently a self-block experiment, where we coinjected 2.1 mg/kg nonlabeled 1 along with [ 11 C]1 ( Figure 3C ). Kinetic modelling of the baseline and self-block PET data confirmed that the binding of [
11 C]1 is quite uniform across the brain. The total distribution volume (V T ) in the baseline situation was the highest in the cortex (5.6 mL/cm ). This is not in accordance with the reported distribution of α 4/6 δ containing GABA A Rs. After administration of unlabeled 1, V T s was decreased in all regions: V T decreased by ∼40% in the hippocampus and cortex, whereas V T decreased by ∼18% in the thalamus and cerebellum (Supporting Information Figure  S3A ) indicating that there is some specific binding of Figure S3B ). Only early eluting radiometabolites were detected with our radio-HPLC method, suggesting that these metabolites were of a polar nature (Supporting Information Figure S4 ). The free fraction of [
11 C] 1 in pig plasma was measured to 15% using a dialysis chamber method with an incubation time of 3 h. This is comparable to other radiotracers evaluated in pigs. 22, 23 In conclusion, we here show a high uptake of [
11 C]1 into the pig brain but the uptake is uniform and clears quickly. However, when the uptake was quantified, we found decreases in binding after self-blockade, indicating some specific binding. In contrast to DS2, 13 [
11 C]1 enters the brain, which, together with its selectivity for δ-containing GABA A Rs, renders 1 a promising lead in developing a radiotracer for the target. Figure S1 ). The labeled product was collected into a sterile 20 mL vial containing phosphate-buffer (9 mL, 100 mM, pH 7). The final product was analyzed by analytical HPLC [Luna, 5μ, C-18(2) 100 Å column (Phenomenex Inc. FMP Blue Assay on GABA A Receptors Expressed in HEK-293 Cells. The FMP assay was performed on HEK-293 Flp-In cells expressing human recombinant GABA A receptors using conditions for cell-culturing and transfection as described previously. 21 In brief, the cells were plated for transfection 24 h later with GABA A receptor plasmids with the Polyfect Transfection Reagent (Qiagen, West Sussex, UK). For expression of the δ-containing GABA A receptor subtypes, α 1 β 2 δ, α 4 β 2 δ, and α 6 β 2 δ, HEK-293 Flp-In cells stably expressing the GABA A δ-subunit were transfected by a 1:1 ratio of either α 1 , α 4 (both pUNIV) (Addgene, Cambridge, MA, USA), 24 or α 6 (pcDNA3.1zeo) and β 2 (pcDNA3.1zeo).
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α 6 β 2 γ 2s receptors were transiently expressed in background HEK-293 Flp-In cells 21 using a 1:1:2 ratio of α 6 -, β 2 -and γ 2s -subunits, respectively.
Transfected cells 16−24 h post-transfection were plated into poly-D-lysine coated black clear bottom 96-well plates (BD Biosciences, Bedford, MA, USA) at a density of 50 000 cells/ well and incubated for 16−20 h. On the day of the assay, the medium was aspirated, and the cells were washed in 100 μL/ well assay buffer [HBSS (Life technologies, Paisley, UK) + 20 mM HEPES pH 7.4] followed by addition of 100 μL/well of the FMP blue dye (0.5 mg/mL) (Molecular Devices, Sunnyvale, CA, USA) and incubated in the dark for 30 min in a CO 2 incubator at 37°C and 5% CO 2 . Ligand solutions were prepared in 5× in assay buffer, which for testing of the PAMs contained a concentration of GABA corresponding to GABA EC 20 . The GABA EC 20 concentrations were determined from full GABA concentration−response curves for each subtype, as described in the Results and Discussion section. Before reading of the plate, the ligand solutions were added to 96-well ligand plates and incubated for 15 min at 37°C in the NOVOstar plate reader (BMG, LABTECH GmbH, Offenburg, Germany). Fluorescence was determined by excitation of the dye at 530 nm and emission at 560 nm. The relative changes in the fluorescent signal (ΔFU) were analyzed by subtracting the baseline signal from the maximum peak/plateau signal induced by the ligands. Fluorescence signals were visually inspected, and any artefacts were manually omitted from the analysis. Concentration−response curves were fitted to obtain EC 50 values using the four-parameter concentration−response curve using GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA) The animal was housed under standard conditions and was allowed to acclimatize for 1 week. Before scanning, anaesthesia was induced with im injection of 0.13 mL/kg Zoletil veterinary mixture (10.87 mg/kg xylazine + 10.87 mg/kg ketamine + 1.74 mg/kg methadone + 1.74 mg/kg butorphanol + 10.87 mg/kg tiletamine + 10.87 mg/kg zolezepam). Thereafter, anaesthesia was maintained with constant propofol infusion [1.5 mg/kg/h intravenous (iv); B. Braun, Melsungen, Germany]. Arterial iv access for drawing blood was granted in the right femoral artery via a minor incision, and two venous iv lines for injections were granted in the left and right mammary veins. Analgesia was assured by iv injection of fentanyl during surgery. During anaesthesia, animals were endotracheally intubated and ventilated. Vital parameters (heart rate, body temperature, blood pressure, blood glucose, oxygen saturation, and end tidal CO 2 ) were continuously monitored during the scan.
Blood Sampling. During the first 30 min of the scans, radioactivity in the whole blood was continuously measured using an ABSS autosampler (Allogg Technology, Mariefred, Sweden) counting coincidences in a lead-shielded detector. Concurrently, arterial whole blood was sampled manually at times 2.5, 5, 10, 20, 30, 40, 50, 70, and 90 min after injection of [ 11 C]1. Total radioactivity in plasma (500 μL) and whole blood (500 μL) was measured in a well counter (Cobra 5003; Packard Instruments, Meriden, CT, USA), which was crosscalibrated to the HRRT scanner and autosampler. All measurements of radioactivity were decay-corrected to the time of radioligand injection. The free fraction of [ 11 C]1 in pig plasma was measured using an equilibrium dialysis method as previously described 26 and calculated as the ratio between radioactivity in a buffer and plasma.
Metabolite analysis. Radiolabelled parent compound and metabolites were determined by direct injection of plasma into a radio-HPLC system (Dionex Ultimate 3000; Thermo Fisher Scientific, Hvidovre, Denmark) configured for column switch-
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Article ing. Manually drawn arterial whole blood samples were centrifuged (1500g, 7 min, 4°C), and plasma was filtered through a syringe filter (Whatman GD/X 13 mm or 25 mm, poly(vinylidene difluoride) membrane, 0.45 μm pore size; Frisenette ApS, Knebel, Denmark) before the analysis by HPLC as previously described. 27 Reconstruction and quantification of PET data. Ninety-minute list-mode PET data were reconstructed in 38 dynamic frames (6 × 10, 6 × 20, 4 × 30, 9 × 60, 2 × 180, 8 × 300, and 3 × 600 s). Images consisted of 207 planes of 256 × 256 voxels of 1.22 × 1.22 × 1.22 mm. A summed picture of all counts in the 90 min scan was reconstructed for the pig and used for coregistration to a multimodal pig brain atlas, as described by Villadsen et all. 28 The time−activity curves were calculated for the following volumes of interest (VOIs): cortex, hippocampus, thalamus, striatum, and cerebellum (excluding the vermis). Outcome measure in the time−activity curves was calculated as the radioactive concentration in the VOI (in kBq/mL) normalized to the injected dose corrected for animal weight (in kBq/kg), yielding standardized uptake values (g/ mL). Quantification of the binding was performed in PMOD (version 3.0) with the Logan graphical analysis, using the metabolite-corrected arterial plasma concentration to calculate the total distribution volume (V T ). 
